Literature DB >> 19950383

Paroxetine exposure during pregnancy and the risk of cardiac malformations: what is the evidence?

Anick Bérard1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19950383     DOI： 10.1002/bdra.20643

Source DB:  PubMed          Journal:  Birth Defects Res A Clin Mol Teratol        ISSN： 1542-0752


× No keyword cloud information.
  5 in total

Review 1.  Investigating outcomes following the use of selective serotonin reuptake inhibitors for treating depression in pregnancy: a focus on methodological issues.

Authors:  Luke E Grzeskowiak; Andrew L Gilbert; Janna L Morrison
Journal:  Drug Saf       Date:  2011-11-01       Impact factor: 5.606

2.  Paroxetine use during pregnancy and the risk of cardiac defects.

Authors:  Anick Bérard; Sonia Chaabane; Flory T Muanda; Takoua Boukhris; Jinping Zhao
Journal:  Br J Clin Pharmacol       Date:  2016-05-20       Impact factor: 4.335

3.  Paroxetine use in pregnancy and increased risk of heart defects: Evaluating the evidence.

Authors:  Adrienne Einarson
Journal:  Can Fam Physician       Date:  2010-08       Impact factor: 3.275

4.  Selective serotonin reuptake inhibitors in human pregnancy: to treat or not to treat?

Authors:  Orna Diav-Citrin; Asher Ornoy
Journal:  Obstet Gynecol Int       Date:  2011-12-10

5.  Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort.

Authors:  Anick Bérard; Jin-Ping Zhao; Odile Sheehy
Journal:  BMJ Open       Date:  2017-01-12       Impact factor: 2.692
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.